REG-Arix Bioscience PLC Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
01/11/2023 16:45
============
Arix Bioscience PLC (ARIX)
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in
Phase 1/1b Clinical Trial of SOR102
01-Nov-2023 / 16:30 GMT/BST
══════════════════════════════════════════════════════════════════════════
Arix Bioscience plc
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in
Phase 1/1b Clinical Trial of SOR102
LONDON, 1 November 2023: Arix Bioscience plc (“Arix” or the “Company”)
(LSE: ARIX), a transatlantic venture capital company focused on investing
in breakthrough biotechnology companies, notes that its Core Portfolio
company, Sorriso Pharmaceuticals (“Sorriso”), has announced that the first
subject has been dosed in the Company’s Phase 1/1b clinical program of
SOR102.
SOR102 is a dual-acting oral biologic treatment targeting TNF⍺ and
IL-23(p19) that is being developed for the treatment of inflammatory bowel
disease (IBD).
This Phase 1 trial is a randomized, double-blind study consisting of three
parts. Parts 1 and 2 will evaluate safety, tolerability and
pharmacokinetics (PK) of single ascending oral doses and multiple oral
doses in healthy participants. Part 3 will evaluate safety, tolerability,
PK, and clinical and biological activity of multiple oral doses of SOR102
in patients with mild to severe ulcerative colitis. The trial is expected
to enrol up to 60 adult participants at sites in the United Kingdom and
Europe.
Ciara Kennedy, Ph.D. CEO at Sorriso, commented: “We are excited to
initiate this first-in-human trial of SOR102 as there remains a
significant need for improved therapies for patients suffering from IBD.
We believe that SOR102, which addresses two validated targets and is
designed to act locally within inflamed GI tissue, has the potential to be
an oral first-line advanced therapy, with a superior efficacy and safety
profile over existing systemically administered biologics and novel oral
therapies.”
Robert Lyne, CEO of Arix, added: “This landmark milestone for Sorriso’s
lead candidate is a very exciting next step demonstrating the Company’s
translational capabilities. Sorriso is addressing an area of truly unmet
need, using a highly innovative targeting approach to give hope to people
suffering with severe immune-mediated diseases such as Crohn’s disease and
ulcerative colitis. We look forward to seeing SOR102 develop as it
advances through the Phase 1 trial.”
The full text from Sorriso’s announcement is reproduced below and can be
accessed on the Sorriso Pharmaceuticals website here:
1 www.sorrisopharma.com/news/
ENDS
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir 2 @arixbioscience.com
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
3 arix@powerscourt-group.com
About Arix Bioscience plc
Arix Bioscience plc is a transatlantic venture capital company focused on
investing in breakthrough biotechnology companies around cutting-edge
advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital,
expertise, and global networks to help accelerate their ideas into
important new treatments for patients. As a listed company, we are able to
bring this exciting growth phase of our industry to a broader range of
investors. 4 www.arixbioscience.com
Sorriso Pharmaceuticals Press Release:
Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b
Clinical Trial of SOR102
First-in-Human Study of Novel Oral Dual-Acting Antibody in Development for
Treatment of Patients with Inflammatory Bowel Disease
SALT LAKE CITY, UT, UNITED STATES, November 1, 2023 /EINPresswire.com/ --
Sorriso Pharmaceuticals, a biopharmaceutical company developing novel oral
antibodies in immune-mediated disease, today announced that the first
subject has been dosed in the company’s Phase 1/1b clinical program of
SOR102. SOR102 is a dual-acting oral biologic treatment targeting TNF⍺ and
IL-23(p19) that is being developed for the treatment of inflammatory bowel
disease (IBD).
“We are excited to initiate this first-in-human trial of SOR102 as there
remains a significant need for improved therapies for patients suffering
from IBD,” said Ciara Kennedy, Ph.D., chief executive officer at Sorriso.
“We believe that SOR102, which addresses two validated targets and is
designed to act locally within inflamed GI tissue, has the potential to be
an oral first-line advanced therapy, with a superior efficacy and safety
profile over existing systemically administered biologics and novel oral
therapies.”
This Phase 1 trial is a randomized, double-blind study consisting of three
parts. Parts 1 and 2 will evaluate safety, tolerability and
pharmacokinetics (PK) of single ascending oral doses and multiple oral
doses in healthy participants. Part 3 will evaluate safety, tolerability,
PK, and clinical and biological activity of multiple oral doses of SOR102
in patients with mild to severe ulcerative colitis. The trial is expected
to enroll up to 60 adult participants at sites in the United Kingdom and
Europe. More information about the trial is available at
www.clinicaltrials.gov, identifier NCT06080048.
About SOR102
SOR102 simultaneously inhibits TNF⍺ and IL-23(p19), two clinically
validated drivers of IBD, providing combination therapy locally within
inflamed tissue with minimal systemic exposure. This dual targeting
approach may increase efficacy through simultaneous blockade of different
mechanisms of IBD.
About Sorriso Pharmaceuticals
Sorriso Pharmaceuticals is a biopharmaceutical company advancing a
pipeline of disease-modifying antibodies for the treatment of
immune-mediated diseases, including Crohn’s disease and ulcerative
colitis. The Sorriso platform generates potent antibodies that can be
delivered orally and are designed to maintain activity throughout the
human intestine.
About Sorriso Pharmaceuticals
For more information, please visit 5 www.sorrisopharma.com
══════════════════════════════════════════════════════════════════════════
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
ISIN: GB00BD045071
Category Code: MSCM
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be
disclosed under the laws of a Member State
Sequence No.: 282110
EQS News ID: 1762895
End of Announcement EQS News Service
══════════════════════════════════════════════════════════════════════════
6 fncls.ssp?fn=show_t_gif&application_id=1762895&application_name=news&site_id=reuters8
References
Visible links
1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=7828bc47334d36703a21da0b14993d56&application_id=1762895&site_id=reuters8&application_name=news
2. mailto:charlotte@arixbioscience.com
3. mailto:arix@powerscourt-group.com
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1762895&site_id=reuters8&application_name=news
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=52e6800e15fe84f958e5b400b355fa5e&application_id=1762895&site_id=reuters8&application_name=news
============Recent news on Arix Bioscience
See all newsREG - Stock Exch Notice Arix Bioscience Plc - Cancellation - Arix Bioscience plc
AnnouncementREG-Arix Bioscience PLC Scheme Effective
AnnouncementREG - Official List - Suspension - Arix Bioscience plc
AnnouncementREG-Arix Bioscience PLC Suspension of Trading in Shares
AnnouncementREG-Arix Bioscience PLC Transaction Update
Announcement